ArticleInternational journal of molecular sciences2026
Ciprofloxacin-Induced Oxidative Stress Promotes a Senescence-like Phenotype in Human Fibroblasts In Vitro.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Fluoroquinolones are effective synthetic broad-spectrum antibiotics, but their use can be associated with persistent adverse effects, sometimes described as fluoroquinolone-induced disability. The molecular mechanisms underlying these effects remain incompletely understood, although accumulating evidence implicates mitochondrial dysfunction, oxidative stress, and DNA damage. We hypothesized that the convergence of these stress responses may promote cellular senescence and thereby contribute to persistent fluoroquinolone-associated adverse effects. We examined three clinically used fluoroquinolones-ciprofloxacin, moxifloxacin, and levofloxacin-in primary human fibroblasts in vitro. Exposure for 7 days revealed that 200 µM ciprofloxacin, but not 200 µM moxifloxacin or 500 µM levofloxacin, induced a senescence-like phenotype characterized by increased senescence-associated β-galactosidase (SA-β-Gal) activity and an elevated senescence index (SI), which integrates increased cell size and autofluorescence measured by imaging flow cytometry. At 7 days, ciprofloxacin did not induce a broad canonical senescence-associated secretory phenotype (SASP) at either the transcriptional or secretory level, consistent with a non-canonical senescence-like state; only a modest increase in IL-1β secretion emerged after 14 days. The ciprofloxacin-induced phenotype was not accompanied by a robust increase in the canonical p53, p16, or p21 protein markers, but was associated with reduced retinoblastoma protein (RB) phosphorylation at Ser795. However, ciprofloxacin removal from the culture medium after 1 or 2 weeks of incubation resulted in the recovery of the resazurin signal to approximately control values by the end of the 3-week experimental period. Ciprofloxacin also increased oxidative stress, as assessed using dihydroethidium and dichlorodihydrofluorescein diacetate. Both the antioxidant Trolox and the mitochondria-targeted antioxidant SkQ3 attenuated the ciprofloxacin-induced increase in SA-β-Gal activity and SI. These findings identify oxidative stress as a putative mediator of ciprofloxacin-induced senescence-like remodeling in human fibroblasts and support further investigation of drug-induced cellular senescence as a potential contributor to persistent fluoroquinolone-associated adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.